Akili has published data backing the efficacy of its childhood attention-deficit hyperactivity disorder (ADHD) video game therapy EndeavorRx in the peer-review journal Nature Digital Medicine. 

The results come from the STARS-Adjunct trial, an open-label study of EndeavorRx (AKL-T01) that supported approval of the app and video game combination in the US and Europe last year.

The digital therapy aims to improve children’s ability to focus by asking them to manage competing tasks and to shift attention between tasks using video game-like graphics and digital rewards via a tablet device.

Given that the majority of children diagnosed with ADHD take medication to help manage their condition, it is important to evaluate the effects of new non-pharmacological interventions in the context of routine care, write the authors of the study.

Read more on pharmaphorum.com